Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
SB204990
65
CHF
CHF 65.00
In stock
AG-CR1-3697-M0011 mgCHF 65.00
AG-CR1-3697-M0055 mgCHF 195.00
| Product Details | |
|---|---|
| Synonyms | (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid; SB-204990 |
| Product Type | Chemical |
| Properties | |
| Formula |
C18H22Cl2O5 |
| MW | 389.3 |
| CAS | 154566-12-8 |
| Purity Chemicals | ≥95% |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO, ethanol or DMF. |
| InChi Key | YTRNLFYTHYWDAU-KDOFPFPSSA-N |
| Smiles | O=C1[C@](CC(O)=O)(O)C[C@@H](CCCCCCC2=CC=C(Cl)C=C2Cl)O1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent ATP citrate lyase (ACLY) inhibitor. ATP citrate lyase (ACLY), a key enzyme for lipid synthesis, is frequently overexpressed or activated in cancer to promote lipid synthesis and tumor progression.
- Cell permeable prodrug form of SB201076.
- Hypolipidemic agent. Fatty acid synthesis and cholesterol synthesis inhibitor in a dose-dependent manner.
- Useful agent for immunometabolism research.
- Orally active in vivo. Shown to block fatty acid synthesis and cancer cell growth in pre-clinical studies.
Product References
- ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo: A.D. Gribble, et al.; J. Med. Chem. 41, 3582 (1998)
- The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076: N.J. Pearce, et al.; Biochem. J. 15, 334 (1998)
- ATP citrate lyase inhibition can suppress tumor cell growth: G. Hatzivassiliou, et al.; Cancer Cell 8, 311 (2005)
- Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression: C. Zhang, et al.; Genes Dev. 30, 1956 (2016)
- Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion: N. Jiang, et al.; Nature Comm.13, 1511 (2022)
Related Products
